Andrew Hantel, MD

Andrew Hantel, MD

Medical Oncology


Andrew Hantel, MD

Andrew Hantel, MD is an Instructor in Medicine at Harvard Medical School and faculty member in the Divisions of Leukemia and Population Sciences at Dana-Farber Cancer Institute and the HMS Center for Bioethics.  He received his MD from Loyola University Chicago; trained in internal medicine, adult hematology/oncology, and medical ethics at the University of Chicago; and completed a post-doctoral fellowship in cancer population sciences at the Dana-Farber/Harvard Cancer Center.  Dr. Hantel's lab leverages health services and care delivery methods to address ethical dilemmas in cancer discovery and delivery.  His current work focuses on equity in the contexts of research participation, artificial intelligence, and climate change.



Instructor of Medicine, Harvard Medical School


Clinical Interests

Health care delivery, Health equity, Leukemias, Medical ethics

Diseases Treated

Board Certification

  • Internal Medicine
  • Medical Oncology


  • The University of Chicago, Hematology/Medical Oncology
  • The University of Chicago, Medical Ethics


  • The University of Chicago Medicine, Internal Medicine

Medical School

  • Loyola University Chicago


    My research applies health services methods to address ethical dilemmas in cancer care delivery.  I primarily focus on identifying inequities in care and outcomes and developing interventions to remediate them.  Specific interests include patient access to and participation in clinical research, the interactions of climate change and cancer health, and the clinical applications of artificial intelligence.  Examples of projects include developing performance feedback tools for physicians to promote clinical trial representativeness, augmenting clinical trial criteria to promote inclusion and safety, and assessing the climate impact of tele-oncology.  I have been fortunate to receive grants for these areas of research from the National Institute of Health, the American Society for Clinical Oncology, the Greenwall Foundation, and the Alliance for Clinical Trials in Oncology.


      • Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia. Haematologica. 2024 Apr 01; 109(4):1046-1052. View in: Pubmed

      • Race/ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia. J Natl Cancer Inst. 2024 Mar 22. View in: Pubmed

      • Perspectives of Oncologists on the Ethical Implications of Using Artificial Intelligence for Cancer Care. JAMA Netw Open. 2024 Mar 04; 7(3):e244077. View in: Pubmed

      • Shifting from Equality toward Equity: Addressing Disparities in Research Participation for Clinical Cancer Research. J Clin Ethics. 2024; 35(1):8-22. View in: Pubmed

      • Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia. Blood Cancer J. 2023 12 21; 13(1):192. View in: Pubmed

      • ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages. J Clin Oncol. 2024 Jan 20; 42(3):358-365. View in: Pubmed

      • Digital Health to Patient-Facing Artificial Intelligence: Ethical Implications and Threats to Dignity for Patients With Cancer. JCO Oncol Pract. 2024 Mar; 20(3):314-317. View in: Pubmed

      • Association of social deprivation with survival in younger adult patients with AML: an Alliance study. Blood Adv. 2023 08 08; 7(15):4019-4023. View in: Pubmed

      • National Cancer Institute Centers With Environmental Sustainability Plans for Climate Change. JAMA Netw Open. 2023 06 01; 6(6):e2317206. View in: Pubmed

      • Environmental Health: Translating Policy Into Action. Ann Intern Med. 2022 Nov; 175(11):1612-1613. View in: Pubmed

      • Ethics Consultation in Oncology: The Search for Quality in Quantity. JCO Oncol Pract. 2022 09; 18(9):610-613. View in: Pubmed

      • A Process Framework for Ethically Deploying Artificial Intelligence in Oncology. J Clin Oncol. 2022 12 01; 40(34):3907-3911. View in: Pubmed

      • Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. J Clin Oncol. 2022 11 10; 40(32):3709-3718. View in: Pubmed

      • Impact of Allocation on Survival During Intermittent Chemotherapy Shortages: A Modeling Analysis. J Natl Compr Canc Netw. 2022 04; 20(4):335-341.e17. View in: Pubmed

      • Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Adv. 2021 11 09; 5(21):4352-4360. View in: Pubmed

      • Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes. Transfusion. 2021 10; 61(10):2830-2836. View in: Pubmed

      • Model solutions for ethical allocation during cancer medicine shortages. Lancet Haematol. 2021 04; 8(4):e246-e248. View in: Pubmed

      • Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223. View in: Pubmed

      • US State Government Crisis Standards of Care Guidelines: Implications for Patients With Cancer. JAMA Oncol. 2021 02 01; 7(2):199-205. View in: Pubmed

      • Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer. 2021 03 15; 127(6):875-883. View in: Pubmed

      • Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 04; 35(4):1166-1175. View in: Pubmed

      • A Qualitative Analysis of Oncology Patient Awareness of Medication Shortages and Their Preferences for How Shortages Should Be Managed. JCO Oncol Pract. 2020 10; 16(10):e1098-e1111. View in: Pubmed

      • An Action Plan for Environmentally Sustainable Cancer Care. JAMA Oncol. 2020 04 01; 6(4):469-470. View in: Pubmed

      • A Cross-Sectional Survey of Medical Trainee Experiences During Medication Shortages. J Grad Med Educ. 2020 Feb; 12(1):38-43. View in: Pubmed

      • Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14(10):e0224097. View in: Pubmed

      • Practical allocation system for the distribution of specialised care during cellular therapy access scarcity. J Med Ethics. 2019 08; 45(8):532-537. View in: Pubmed

      • Prevalence and Severity of Rationing During Drug Shortages: A National Survey of Health System Pharmacists. JAMA Intern Med. 2019 05 01; 179(5):710-711. View in: Pubmed

      • Imatinib is still recommended for frontline therapy for CML. Blood Adv. 2018 12 26; 2(24):3648-3652. View in: Pubmed

      • Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018 07 16; 6(1):73. View in: Pubmed

      • Creating Coherent Strategies to Combat the Crises of Opioid Scarcity and Abuse. J Clin Oncol. 2018 09 01; 36(25):2575-2577. View in: Pubmed

      • Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):636-647. View in: Pubmed

      • A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning. J Palliat Med. 2018 06; 21(6):846-849. View in: Pubmed

      • Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7. View in: Pubmed

      • TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016 11 24; 375(21):2023-2036. View in: Pubmed

      • No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. J Oncol Pract. 2016 10; 12(10):e901-e911. View in: Pubmed

      • Drug and vaccine access in the Ebola epidemic: advising caution in compassionate use. Ann Intern Med. 2015 Jan 20; 162(2):141-2. View in: Pubmed

      • A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma. 2014 Dec; 55(12):2945-6. View in: Pubmed

      • A protocol and ethical framework for the distribution of rationed chemotherapy. J Clin Ethics. 2014; 25(2):102-15. View in: Pubmed

      • Analysis of very elderly (=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012 Jan; 156(2):196-204. View in: Pubmed


      Location Avtar

      Dana Building

      450 Brookline Ave. Boston, MA 02215
      Get Directions

      Dana Building

      Location Avtar

      Dana Building

      450 Brookline Ave. Boston, MA 02215
      Get Direction
      42.3374, -71.1082